天下秀(600556.SH):擬斥9900萬元認購深圳晨源份額 佔投後比例19.80%
格隆匯11月26日丨天下秀(600556.SH)宣佈,為了促進公司長遠發展,優化投資結構,充分藉助專業投資機構的專業資源與投資管理優勢,公司擬以自有資金9900萬元認購深圳晨源的出資份額,併成為該合夥企業的有限合夥人。該次投資完成後,深圳晨源認繳出資總額將增加至人民幣5億元,公司屆時將持有該合夥企業19.80%的出資份額。
深圳晨源為有限合夥人深圳市引導基金投資有限公司、有限合夥人深圳市福田引導基金投資有限公司、有限合夥人嘉興同源股權投資合夥企業(有限合夥)與普通合夥人深圳晨源諮詢管理合夥企業(有限合夥)共同發起設立的私募創業投資基金,主要投資領域集中於互聯網、高科技創新企業。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.